1. Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behçet's disease: an open-label pilot study. Issue 4 (14th November 2011) Authors: Gül, Ahmet; Tugal-Tutkun, Ilknur; Dinarello, Charles A; Reznikov, Leonid; Esen, Bahar Artim; Mirza, Amer; Scannon, Patrick; Solinger, Alan Journal: Annals of the rheumatic diseases Issue: Volume 71:Issue 4(2012) Page Start: 563 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Issue 9 (26th June 2018) Authors: Baeten, Dominique; Østergaard, Mikkel; Wei, James Cheng-Chung; Sieper, Joachim; Järvinen, Pentti; Tam, Lai-Shan; Salvarani, Carlo; Kim, Tae-Hwan; Solinger, Alan; Datsenko, Yakov; Pamulapati, Chandrasena; Visvanathan, Sudha; Hall, David B; Aslanyan, Stella; Scholl, Paul; Padula, Steven J Journal: Annals of the rheumatic diseases Issue: Volume 77:Issue 9(2018) Page Start: 1295 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗